D.E. Shaw & Co’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$62.6M Buy
178,009
+149,032
+514% +$53.1M 0.04% 569
2025
Q4
$9.48M Sell
28,977
-99,882
-78% -$31.7M 0.01% 1803
2025
Q3
$36.4M Sell
128,859
-496,222
-79% -$144M 0.02% 819
2025
Q2
$175M Sell
625,081
-635,803
-50% -$180M 0.12% 183
2025
Q1
$393M Sell
1,260,884
-713,329
-36% -$211M 0.35% 34
2024
Q4
$515M Buy
1,974,213
+1,807,767
+1,086% +$536M 0.38% 33
2024
Q3
$53.6M Sell
166,446
-140,234
-46% -$45.9M 0.05% 476
2024
Q2
$95.8M Sell
306,680
-107,056
-26% -$31.5M 0.09% 266
2024
Q1
$118M Sell
413,736
-142,016
-26% -$41.6M 0.1% 221
2023
Q4
$160M Sell
555,752
-260,814
-32% -$71.1M 0.14% 156
2023
Q3
$219M Buy
816,566
+36,003
+5% +$8.98M 0.23% 76
2023
Q2
$173M Buy
780,563
+462,329
+145% +$107M 0.18% 115
2023
Q1
$76.9M Sell
318,234
-931,891
-75% -$229M 0.08% 290
2022
Q4
$328M Buy
1,250,125
+447,032
+56% +$120M 0.36% 27
2022
Q3
$181M Sell
803,093
-168,018
-17% -$40.7M 0.22% 77
2022
Q2
$236M Buy
971,111
+40,015
+4% +$9.81M 0.28% 42
2022
Q1
$225M Sell
931,096
-543,418
-37% -$125M 0.21% 68
2021
Q4
$332M Buy
1,474,514
+218,444
+17% +$46.1M 0.28% 45
2021
Q3
$267M Buy
1,256,070
+109,648
+10% +$25.2M 0.24% 59
2021
Q2
$279M Buy
1,146,422
+308,427
+37% +$75.9M 0.24% 66
2021
Q1
$209M Buy
837,995
+665,063
+385% +$159M 0.2% 87
2020
Q4
$39.8M Buy
172,932
+76,361
+79% +$17.6M 0.04% 601
2020
Q3
$24.5M Sell
96,571
-124,129
-56% -$30.8M 0.03% 723
2020
Q2
$52.1M Sell
220,700
-711,280
-76% -$162M 0.06% 347
2020
Q1
$189M Buy
931,980
+669,822
+256% +$146M 0.29% 51
2019
Q4
$63.2M Sell
262,158
-980,762
-79% -$216M 0.07% 318
2019
Q3
$241M Sell
1,242,920
-79,411
-6% -$15.2M 0.3% 52
2019
Q2
$244M Sell
1,322,331
-298,165
-18% -$53.4M 0.3% 50
2019
Q1
$308M Buy
1,620,496
+1,107,989
+216% +$212M 0.4% 36
2018
Q4
$99.8M Buy
512,507
+4,696
+0.9% +$916K 0.14% 169
2018
Q3
$105M Sell
507,811
-80,756
-14% -$15.9M 0.13% 190
2018
Q2
$109M Sell
588,567
-212,219
-27% -$37.5M 0.14% 165
2018
Q1
$137M Sell
800,786
-1,664,954
-68% -$306M 0.19% 118
2017
Q4
$429M Buy
2,465,740
+823,332
+50% +$146M 0.59% 16
2017
Q3
$306M Sell
1,642,408
-870,694
-35% -$154M 0.47% 25
2017
Q2
$433M Buy
2,513,102
+776,837
+45% +$126M 0.72% 12
2017
Q1
$285M Buy
1,736,265
+362,174
+26% +$60.2M 0.5% 23
2016
Q4
$201M Buy
1,374,091
+990,998
+259% +$149M 0.34% 46
2016
Q3
$63.9M Sell
383,093
-1,285,912
-77% -$217M 0.11% 217
2016
Q2
$254M Sell
1,669,005
-1,304,947
-44% -$203M 0.47% 28
2016
Q1
$446M Buy
2,973,952
+446,710
+18% +$66.4M 0.8% 9
2015
Q4
$410M Buy
2,527,242
+1,100,809
+77% +$173M 0.61% 17
2015
Q3
$197M Buy
1,426,433
+925,263
+185% +$146M 0.29% 62
2015
Q2
$76.9M Sell
501,170
-128,402
-20% -$20.6M 0.11% 209
2015
Q1
$101M Sell
629,572
-297,067
-32% -$46.8M 0.15% 146
2014
Q4
$148M Sell
926,639
-363,441
-28% -$56.6M 0.19% 96
2014
Q3
$181M Buy
1,290,080
+1,045,349
+427% +$136M 0.23% 71
2014
Q2
$29M Buy
244,731
+231,791
+1,791% +$26.8M 0.04% 507
2014
Q1
$1.6M Sell
12,940
-479,301
-97% -$58.1M ﹤0.01% 2608
2013
Q4
$56.2M Sell
492,241
-5,658
-1% -$644K 0.08% 278
2013
Q3
$55.7M Sell
497,899
-875,710
-64% -$95M 0.09% 237
2013
Q2
$136M Buy
+1,373,609
New +$143M 0.25% 61

Other funds holding AMGN

D.E. Shaw & Co's AMGN Position: Q1 2026 in Review

D.E. Shaw & Co increased its Amgen (AMGN) stake by 514% in Q1 2026, buying an estimated $53.1M and bringing the position to 178,009 shares worth $62.6M. The position accounts for 0.04% of the portfolio, ranked #569.

D.E. Shaw & Co first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $515M in Q4 2024. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • D.E. Shaw & Co held 178,009 shares of Amgen worth $62.6M as of Q1 2026.
  • D.E. Shaw & Co bought 149,032 Amgen shares in Q1 2026, an estimated $53.1M.
  • Amgen made up 0.04% of D.E. Shaw & Co's portfolio in Q1 2026, its #569 holding.
  • D.E. Shaw & Co first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • D.E. Shaw & Co's Amgen position peaked at $515M in Q4 2024.
  • 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.